Category: Pharmaceuticals

Pharmaceuticals

Health Canada OKs Ivacaftor for Cystic Fibrosis Patients Down to 2 Months

Health Canada granted market authorization for the expanded use of ivacaftor to treat cystic fibrosis in certain children ages 2 months and older.

Pharmaceuticals

Immunotherapy Before and After Surgery Boosts Lung Cancer Outcomes

Pre- and post-surgical immunotherapy, combined with chemotherapy, improved survival rates for patients with operable non-small cell lung cancer in a phase 3 trial.

Pharmaceuticals

RSV Monoclonal Antibody in Short Supply

Sanofi issued an advisory to notify healthcare providers and consumers of a "unprecedented" and "higher than anticipated" demand for its recently-approved RSV monoclonal antibody, nirsevimab-alip (Beyfortus).

Clinical Trials

Cystic Fibrosis mRNA Therapeutic Candidate Gets Funding Boost

The Cystic Fibrosis Foundation is investing up to $9 million in additional funds in Arcturus Therapeutics to test ARCT-032, an inhaled messenger RNA therapeutic candidate that could treat the underlying cause of cystic fibrosis in all people living with the disease.

US Pharmaceuticals

Positive Data for Moderna Flu-COVID Vaccine Combo

Moderna reported positive interim results from the Phase 1/2 trial of its combination vaccine against influenza and COVID-19.

Intl' Pharmaceuticals

Pfizer and BioNTech Get Positive EU Opinion for Updated COVID-19 Vaccine

The companies also filed an application with the FDA requesting approval of their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine for individuals 6 months of age and older.